Resectable pancreatic cancer: diagnosis criterion, treatment and controversy

doi:10.16139/j.1007-9610.2022.01.002

Abstract

CLC Number:

R735.9

HE Min, LIU Yingbin. Resectable pancreatic cancer: diagnosis criterion, treatment and controversy[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 6-10.

References 31

[1]	Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014[J]. CA Cancer J Clin, 2014, 64(1):9-29. doi: 10.3322/caac.21208 URL
[2]	Margaret A, Tempero MD, Mokenge P, et al. Pancreatic adenocarcinoma,version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457. doi: 10.6004/jnccn.2021.0017 URL
[3]	Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas[J]. J Gastmintest Surg, 2001, 5(1):27-35.
[4]	Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma,version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210. doi: 10.6004/jnccn.2019.0014 URL
[5]	Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma:reassessment by thin-section CT[J]. Abdom Imaging, 1996, 21(3):202-206. pmid: 8661548
[6]	Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT[J]. Am J Roentgenol, 1997, 168(6):1439-1443. pmid: 9168704
[7]	殷允娟, 曾蒙苏, 李卉, 等. MRI对胰腺癌胰周血管侵犯的手术可切除性评价[J]. 临床放射学杂志, 2005, 24(9):792-796.
[8]	李卉, 曾蒙苏, 周康荣, 等. 胰腺癌侵犯胰周主要血管的CT表现分析[J]. 中华放射学杂志, 2005, 39(3):293-297.
[9]	Katz MH, Fleming JB. Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant the-rapy is not reflected by radiographic indicators[J]. Cancer, 2012, 8(23):5749-5756.
[10]	Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRlNOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17. doi: 10.1097/SLA.0000000000000867 URL
[11]	Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy[J]. Ann Surg Oncol, 2013, 20(7):2188-2196. doi: 10.1245/s10434-012-2809-1 pmid: 23247983
[12]	Ferrone CR, Finkelstein DM, Thayer SP, et al. Periope-rative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma[J]. J Clin Oncol, 2006, 24(18):2897-2902. doi: 10.1200/JCO.2005.05.3934 URL
[13]	徐华祥, 徐帅帅, 李硕, 等. 术前血清CA125预测血清CA19-9正常胰腺癌病人术后生存的价值[J]. 中国临床医学, 2020, 27(1):50-54.
[14]	Abrams RA, Lowy AM, O′ Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer; expert consensus statement[J]. Ann Surg Oncol, 2009, 16(7):1751-1756. doi: 10.1245/s10434-009-0413-9 pmid: 19390900
[15]	中国临床肿瘤学会胰腺癌专家委员会. 胰腺癌综合诊治中国专家共识(2014年版)[J]. 临床肿瘤学杂志, 2014,(4):358-370.
[16]	刘颖斌, 吴文广. 基于胰腺全系膜切除理念的胰头癌整块切除原则[J]. 外科理论与实践, 2015, 20(6):476-478.
[17]	刘颖斌, 吴文广. 胰头癌根治性切除的范围与争议[J]. 中华消化外科杂志, 2015, 14(8):615-618.
[18]	郝纯毅, 刘续宝, 孙备, 等. 可能切除胰腺癌治疗的现状与争议[J]. 中华消化外科杂志, 2018, 17(7):677-681.
[19]	Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer:an intention to treat analysis[J]. Eur J Surg Oncol, 2018, 44(10):1619-1623. doi: S0748-7983(18)31260-5 pmid: 30146251
[20]	Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma[J]. Surgery, 2012, 152(5):851-862. doi: 10.1016/j.surg.2012.03.010 URL
[21]	白雪莉, 粟伟, 李想, 等. 新辅助治疗对胰腺癌术后并发症的影响[J]. 中华外科杂志, 2018, 56(11):805-808.
[22]	Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic bodyradiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma[J]. Acta Oncol, 2015, 54(7):979-985. doi: 10.3109/0284186X.2015.1004367 pmid: 25734581
[23]	Le Seodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially reseetable pancreatic adenocarcinoma:feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review[J]. Ann Oncol, 2009, 20(8):1387-1396. doi: 10.1093/annonc/mdp015 URL
[24]	Leone F, Gatti M, Massucco P, et al. Induction gem-citabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for nemdjuvant treatment of locally advanced pancreatic cancer: a single institutional experience[J]. Cancer, 2012, 119(2):277-284. doi: 10.1002/cncr.27736 URL
[25]	Lee SE, Jang JY, Kim MA, et al. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer[J]. J Korean Med Sci, 2011, 26(7):881-885. doi: 10.3346/jkms.2011.26.7.881 URL
[26]	Kim N, Han IW, Ryu Y, et al. Predictive nomogram for early recurrence after pancreatectomy in resectable pancreatic cancer: risk classification using preoperative clinicopathologic factors[J]. Cancers(Basel), 2020, 12(1):E137.
[27]	Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma(PACT-15): a randomised, open-label, phase 2-3 trial[J]. Lancet Gastroenterol He-patol, 2018, 3(6):413-423.
[28]	Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02 / JSAP05)[J]. Jpn J Clin Oncol, 2019, 49(2):190-194. doi: 10.1093/jjco/hyy190 URL
[29]	Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative / neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267. doi: 10.1371/journal.pmed.1000267 URL
[30]	Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postope-rative complications[J]. Ann Surg Oncol, 2018, 25(3):626-637. doi: 10.1245/s10434-017-6281-9 pmid: 29214453
[31]	Dahdaleh FS, Naffouje SA, Hanna MH, et al. Impact of neoadjuvant systemic therapy on pancreatic fistula rates following pancreatectomy: a population-based propensity- matched analysis[J]. J Gastrointest Surg, 2021, 25(3):747-756. doi: 10.1007/s11605-020-04581-y URL

Resectable pancreatic cancer: diagnosis criterion, treatment and controversy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Hongzhan, ZHANG Kai. Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320.
[2]	GAO Pan, CAI Yunqiang, PENG Bing. Function-preserving laparoscopic resection of pancreatic head and duodenal papilla tumors [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 190-196.
[3]	YU Lan, ZHANG Yongyi, HUANG Lei, WAN Xin, JIANG Shengyao, TANG Sijing, ZHANG Jun, HU Weiguo. Risk factors of severe postoperative complications in elderly patients with pancreaticoduodenectomy [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 139-146.
[4]	XIE Xuehai, YANG Yinmo. Evaluation and technical key points of pancreaticojejunostomy [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 1-5.
[5]	SHI Yihua, JI Shunrong, XU Xiaowu, YU Xianjun. Minimally invasive enucleation of pancreatic tumor: technical note and thinking [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 14-18.
[6]	LI Ji, FU Deliang, NI Quanxing. Surgical decision making for pancreatic cystic neoplasm: selection of local enucleation [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 19-21.
[7]	WU Lili, XU Yaolin, LOU Wenhui. Radiotherapy in management of pancreatic cancer: application and prospect [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 25-29.
[8]	WANG Chong, CHENG Shi. Consensus and controversy: preoperative biliary drainage for resectable pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 30-33.
[9]	WANG Wei, HUA Jie. Common vascular variations and coping strategies in pancreaticoduodenectomy [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 34-38.
[10]	WEI Jishu, HUANG Shimeng. Perineural invasion and neural plasticity in pancreatic cancer: study history and current treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 42-45.
[11]	YANG Chunxue, XU Haimin, DA Qian. Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 52-57.
[12]	XU Yu, ZHANG Junfeng, HUA Rong. Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 83-86.
[13]	LUO Danyang, GAO Yiming. Study on oral microflora related to pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 84-86.
[14]	DING Fangmi, LIU Zhendong. Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway [J]. Journal of Surgery Concepts & Practice, 2020, 25(06): 486-492.
[15]	QIAN Lihan, SHN Baiyong. Research progress on comprehensive treatment of locally advanced pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2020, 25(05): 442-446.